SunTrust Banks Weighs in on Tetraphase Pharmaceuticals, Inc.’s FY2017 Earnings (TTPH)
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) – Investment analysts at SunTrust Banks lifted their FY2017 EPS estimates for shares of Tetraphase Pharmaceuticals in a report issued on Thursday. SunTrust Banks analyst E. Nash now anticipates that the biopharmaceutical company will post earnings of ($2.93) per share for the year, up from their previous estimate of ($2.97). SunTrust Banks also issued estimates for Tetraphase Pharmaceuticals’ Q4 2017 earnings at ($0.69) EPS, Q1 2018 earnings at ($0.61) EPS, Q2 2018 earnings at ($0.62) EPS, Q3 2018 earnings at ($0.60) EPS, Q4 2018 earnings at ($0.58) EPS, FY2018 earnings at ($2.31) EPS, FY2019 earnings at ($2.18) EPS, FY2020 earnings at ($0.95) EPS and FY2021 earnings at $0.35 EPS.
A number of other equities research analysts also recently commented on the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $13.00 target price on shares of Tetraphase Pharmaceuticals in a report on Tuesday, September 12th. Piper Jaffray Companies initiated coverage on Tetraphase Pharmaceuticals in a report on Monday, August 28th. They set an “overweight” rating and a $14.00 target price for the company. BMO Capital Markets reaffirmed an “outperform” rating and set a $13.00 target price (up previously from $12.00) on shares of Tetraphase Pharmaceuticals in a report on Wednesday, July 26th. HC Wainwright initiated coverage on Tetraphase Pharmaceuticals in a report on Tuesday, July 11th. They set a “buy” rating and a $15.00 target price for the company. Finally, ValuEngine downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $15.15.
Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at $6.40 on Monday. Tetraphase Pharmaceuticals has a twelve month low of $3.39 and a twelve month high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.63). Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The firm had revenue of $4.10 million during the quarter, compared to the consensus estimate of $1.59 million. During the same quarter in the previous year, the company posted ($0.58) earnings per share. The company’s revenue was up 355.6% compared to the same quarter last year.
Large investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new position in Tetraphase Pharmaceuticals in the third quarter valued at approximately $107,000. AXA acquired a new position in Tetraphase Pharmaceuticals in the second quarter valued at approximately $132,000. Citadel Advisors LLC lifted its holdings in Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock valued at $146,000 after acquiring an additional 2,496 shares during the period. Virtu KCG Holdings LLC acquired a new position in Tetraphase Pharmaceuticals in the second quarter valued at approximately $147,000. Finally, Voya Investment Management LLC lifted its holdings in Tetraphase Pharmaceuticals by 17.8% in the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 3,104 shares during the period. 42.68% of the stock is owned by institutional investors.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 7,155 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $5.86, for a total value of $41,928.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 33,405 shares of company stock valued at $199,691 over the last three months. 5.50% of the stock is currently owned by corporate insiders.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Stock Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.